Posts tagged: disease

Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System Jiwon Oh and Michael Levy Department of Neurology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Pathology 509, Baltimore, MD 21287, USA Received 7 July 2011; Revised 4 October 2011; Accepted 13 October 2011 Academic Editor: Philippe Cabre Copyright ? 2012 Jiwon Oh and Michael Levy

Sexual dysfunction in patients with neurologic disorders ? Contributors Jasvinder Chawla MD MBA , author. Dr. Chawla of Loyola University Medical Center and Hines VA Hospital has no relevant financial relationships to disclose

Optimized Azathioprine Can Be Effective for Neuromyelitis Optica Weight-based dosing, laboratory monitoring for biologic effect, and concurrent use of prednisone are important for treatment success. Azathioprine is often used to prevent relapses in patients with neuromyelitis optica (NMO), but data on its efficacy are limited.

Step by step on a long road to recovery After more than five months in the hospital being treated for a rare disease, Caroline Hinckley, left, is home with her family, including her mother Kristie, and on the mend. (Troy R. Bennett / The Times Record) Brunswick teenager battles back from debilitating Devic’s Disease By Darcie Moore, Times Record Staff Published: Tuesday, July 12, 2011 2:18 PM EDT BRUNSWICK — Approximately eight months have passed since the symptoms of a rare autoimmune disease landed Caroline Hinckley, now 17, in the emergency room at Maine Medical Center in Portland and down a long road to diagnoses, treatment and painful baby steps toward recovery.

Keywords: Neuromyelitis optica; Systemic lupus erythematosus; Systemic Sjogren’s; Myelitis; Autoantibody Abstract Objective: To identify the presence of neuromyelitis optica spectrum disorders (NMOSD) in patients with acute myelitis and suspected connective tissue disease (CTD), and to discuss the utility of this distinction in establishing a diagnostic and therapeutic plan. Methods: Seventeen patients with myelitis were identified from a single university-based rheumatology clinic and prospectively followed. Clinical data and serologic profile were used to determine the presence of neuromyelitis optica (NMO) or NMOSD according to established criteria

Mayo Clinic Researcher Receives AAN’s Dystel Prize for Multiple Sclerosis Research Released: 3/31/2011 8:00 PM EDT Source: American Academy of Neurology (AAN) ? Newswise — HONOLULU – The American Academy of Neurology (AAN) is awarding the 2011 John Dystel Prize for Multiple Sclerosis Research to Brian G. Weinshenker, MD, of the Mayo Clinic in Rochester, Minnesota and a Fellow with the AAN. Weinshenker will receive the award during the AAN’s 63rd Annual Meeting in in Honolulu, held April 9 through April 16, 2011

In 1894, Eug?ne Devic (1858–1930) described a 45-year-old female hatter in whom ‘l’autopsie r?v?la l’existence d’un foyer de my?lite aigu? diffuse localis?e ? la r?gion du renflement lombaire et d’une n?vrite optique double bien marqu?e’ … the autopsy showed a focus of acute diffuse myelitis localized to the lumbar enlargement, as well as a distinct bilateral optic neuritis (Devic, 1894 ). He called the condition ‘neuromy?lite optique aig?e’

The NSCIA Difference Founded in 1948, the National Spinal Cord Injury Association is the nation’s oldest and largest civilian organization dedicated to improving the quality of life for hundreds of thousands of Americans living with the results of spinal cord injury and disease (SCI/D) and their families. This number grows by thirty newly-injured people each day. At NSCIA, we educate and empower survivors of spinal cord injury and disease to achieve and maintain the highest levels of independence, health and personal fulfillment

My notes of reading/lectures/thoughts about neuromyelitis optica (Devic’s disease).

Imaging Immune-Mediated Depression and Cognitive Impairment in Autoimmune Neurologic Diseases: MRS of Patients with Multiple Sclerosis and Transverse Myselitis Adam I. Kaplin, M.D., Ph.D.

Anti–Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica Lukmanee Tradtrantip PhD 1 , Hua Zhang PhD 1 , Samira Saadoun PhD 2 , Puay-Wah Phuan PhD 1 , Chiwah Lam BS 3 , Marios C.

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Pellkofer HL , Krumbholz M , Berthele A , Hemmer B , Gerdes LA , Havla J , Bittner R , Canis M , Meinl E , Hohlfeld R , Kuempfel T